High Zika Virus Seroprevalence in Salvador, Northeastern Brazil Limits the Potential for Further Outbreaks
Eduardo Martins Netto,
Andres Moreira-Soto,
Celia Pedroso,
Christoph Höser,
Sebastian Funk,
Adam J. Kucharski,
Alexandra Rockstroh,
Beate M. Kümmerer,
Gilmara Souza Sampaio,
Estela Luz,
Sara Nunes Vaz,
Juarez Pereira Dias,
Fernanda Anjos Bastos,
Renata Cabral,
Thomas Kistemann,
Sebastian Ulbert,
Xavier de Lamballerie,
Thomas Jaenisch,
Oliver J. Brady,
Christian Drosten,
Manoel Sarno,
Carlos Brites,
Jan Felix Drexler
Affiliations
Eduardo Martins Netto
Hospital Universitário Professor Edgard Santos, Universidade Federal de Bahia, Salvador, Brazil
Andres Moreira-Soto
Institute of Virology, University of Bonn Medical Centre, Bonn, Germany
Celia Pedroso
Hospital Universitário Professor Edgard Santos, Universidade Federal de Bahia, Salvador, Brazil
Christoph Höser
Institute for Hygiene and Public Health, GeoHealth Centre, WHO Collaborating Centre for Health Promoting Water Management & Risk Communication, University of Bonn, Bonn, Germany
Sebastian Funk
Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom
Adam J. Kucharski
Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom
Alexandra Rockstroh
Department of Immunology, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany
Beate M. Kümmerer
Institute of Virology, University of Bonn Medical Centre, Bonn, Germany
Gilmara Souza Sampaio
Hospital Universitário Professor Edgard Santos, Universidade Federal de Bahia, Salvador, Brazil
Estela Luz
Hospital Universitário Professor Edgard Santos, Universidade Federal de Bahia, Salvador, Brazil
Sara Nunes Vaz
Hospital Universitário Professor Edgard Santos, Universidade Federal de Bahia, Salvador, Brazil
Juarez Pereira Dias
Hospital Universitário Professor Edgard Santos, Universidade Federal de Bahia, Salvador, Brazil
Fernanda Anjos Bastos
Maternidade Climério de Oliveira, Universidade Federal da Bahia, Salvador, Brazil
Renata Cabral
Maternidade Climério de Oliveira, Universidade Federal da Bahia, Salvador, Brazil
Thomas Kistemann
Institute for Hygiene and Public Health, GeoHealth Centre, WHO Collaborating Centre for Health Promoting Water Management & Risk Communication, University of Bonn, Bonn, Germany
Sebastian Ulbert
Department of Immunology, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany
Xavier de Lamballerie
Aix Marseille Université, IRD French Institute of Research for Development, EHESP French 19 School of Public Health, EPV UMR_D 190 “Emergence des Pathologies Virales,” Marseille, France
Thomas Jaenisch
German Centre for Infection Research (DZIF), Germany
Oliver J. Brady
Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom
Christian Drosten
German Centre for Infection Research (DZIF), Germany
Manoel Sarno
Hospital Universitário Professor Edgard Santos, Universidade Federal de Bahia, Salvador, Brazil
Carlos Brites
Hospital Universitário Professor Edgard Santos, Universidade Federal de Bahia, Salvador, Brazil
Jan Felix Drexler
Institute of Virology, University of Bonn Medical Centre, Bonn, Germany
ABSTRACT During 2015 to 2016, Brazil reported more Zika virus (ZIKV) cases than any other country, yet population exposure remains unknown. Serological studies of ZIKV are hampered by cross-reactive immune responses against heterologous viruses. We conducted serosurveys for ZIKV, dengue virus (DENV), and Chikungunya virus (CHIKV) in 633 individuals prospectively sampled during 2015 to 2016, including microcephaly and non-microcephaly pregnancies, HIV-infected patients, tuberculosis patients, and university staff in Salvador in northeastern Brazil using enzyme-linked immunosorbent assays (ELISAs) and plaque reduction neutralization tests. Sera sampled retrospectively during 2013 to 2015 from 277 HIV-infected patients were used to assess the spread of ZIKV over time. Individuals were georeferenced, and sociodemographic indicators were compared between ZIKV-positive and -negative areas and areas with and without microcephaly cases. Epidemiological key parameters were modeled in a Bayesian framework. ZIKV seroprevalence increased rapidly during 2015 to 2016, reaching 63.3% by 2016 (95% confidence interval [CI], 59.4 to 66.8%), comparable to the seroprevalence of DENV (75.7%; CI, 69.4 to 81.1%) and higher than that of CHIKV (7.4%; CI, 5.6 to 9.8%). Of 19 microcephaly pregnancies, 94.7% showed ZIKV IgG antibodies, compared to 69.3% of 257 non-microcephaly pregnancies (P = 0.017). Analyses of sociodemographic data revealed a higher ZIKV burden in low socioeconomic status (SES) areas. High seroprevalence, combined with case data dynamics allowed estimates of the basic reproduction number R0 of 2.1 (CI, 1.8 to 2.5) at the onset of the outbreak and an effective reproductive number Reff of <1 in subsequent years. Our data corroborate ZIKV-associated congenital disease and an association of low SES and ZIKV infection and suggest that population immunity caused cessation of the outbreak. Similar studies from other areas will be required to determine the fate of the American ZIKV outbreak. IMPORTANCE The ongoing American Zika virus (ZIKV) outbreak involves millions of cases and has a major impact on maternal and child health. Knowledge of infection rates is crucial to project future epidemic patterns and determine the absolute risk of microcephaly upon maternal ZIKV infection during pregnancy. For unknown reasons, the vast majority of ZIKV-associated microcephaly cases are concentrated in northeastern Brazil. We analyzed different subpopulations from Salvador, a Brazilian metropolis representing one of the most affected areas during the American ZIKV outbreak. We demonstrate rapid spread of ZIKV in Salvador, Brazil, and infection rates exceeding 60%. We provide evidence for the link between ZIKV and microcephaly, report that ZIKV predominantly affects geographic areas with low socioeconomic status, and show that population immunity likely caused cessation of the outbreak. Our results enable stakeholders to identify target populations for vaccination and for trials on vaccine efficacy and allow refocusing of research efforts and intervention strategies.